LinkedIn IconTwitter Icon
14-16 November 2017
The Westin Grand Munich, Germany

Day One
Wednesday 15th November, 2017

Day Two
Thursday 16th November, 2017

Chairs Opening Remarks

  • Tom Lillie VP, Head of European Clinical Development , Merck Sharp & Dohme

Advanced Biomarker Diagnostics

Exploring Immuno-Oncology Combinations – Biology, Big Data & Biomarkers

  • Tom Lillie VP, Head of European Clinical Development , Merck Sharp & Dohme


• Leveraging big data to transform target selection and drug discovery
• Clinical utility of this approach in developing predictive biomarkers for immune checkpoint modulation
• Developing a framework for understanding efficacy in combination with chemoTx, targeted agents, vaccines and immuno-modulators

Harnessing Liquid Biopsies for Disease Monitoring: The Evolving Role of Circulating Tumour Cells as Informative Biomarkers


• Exploring the role for CTCs as biomarkers that can rapidly inform therapy resistance, treatment selection and disease recurrence
• Identifying treatment influenced alterations to ensure more tailored and rapid therapeutic decisions
• Strategies for overcoming background noise and sensitivity issues to identify nuances in patient responses

Speed Networking & Light Refreshments

The Interrelationships Between Mutational Load, Mismatch Repair, & Immune Checkpoint Expression


• Providing biological background by which somatic mutations can lead to the generation of private, highly immunogenic tumour antigens (neoantigens)
• Discussing association of mutational burden with response to immune-checkpoint blockade in solid tumours
• Providing outlook on clinical applications involving mutational load and neoantigens

Panel Discussion: Challenges & Perspectives of Immunotherapy Biomarkers


• How to maximise the value of biomarkers in immuno oncology
• Discussing the key role that biomarkers of immune function, such as Immunoscore, will play in the development of next generation immunotherapies
• What role should companion and complementary diagnostics play in future therapeutic development?
• Technical shortcomings of single biomarker models
• Clinical utility of PD-L1 immunohistochemistry in identifying responders to immune modulation
• Beyond PD-L1 immunohistochemistry – potential of RNA- and DNA-based assays to identify responders to therapeutics

Lunch & Networking

Adaptive Preclinical Designs to Determine Clinical Efficacy of Checkpoint Therapeutics

Requirements for Improved Preclinical Models for More Rapid Clinical Development in Immuno-Oncology


• Demonstrating preclinical data that led to vaccine plus checkpoint inhibitor (Prostvac + Nivo + IPI and CV-301 + anti-PD-1)
• Showcasing the inefficiencies of preclinical models in IO therapy as inadequate in selecting optimal combination strategies
• Exploring the ideal characteristics of a model for preclinical assessment of cancer immunotherapy
• Highlighting a need to shift business models to allow therapeutic companies to evaluate these models with lower risk until validation is complete

Modelling Aspects of the TME in Order to Guide Development of Novel Immune Modulating Cancer Therapies


  • The complexity of the immune regulatory networks that exist within tumours provides many novel potential targets for immunotherapy.
  • Providing human cellular models for mechanism determination and compound selection.
  • Predicting efficacy in early clinical trials using directed PD biomarker strategies.

A Cellular Platform for the Evaluation of Immune Checkpoints


• Developing a novel platform for studying human immune checkpoints
• Showcasing data highlighting this system as a powerful tool to evaluate immune checkpoint inhibitors
• Sharing novel insights into the distinct mechanisms of PD-1, CTLA-4, TIGIT, LAG-3 and BTLA to inhibit T cell activation
• Revealing combination data of PD-1 and BTLA as potently enhancing human T cell responses

CANscript: A Clinically Validated, Ex Vivo Tumor Culture Platform for Interrogating Response to Drug Treatment

  • Mark Paris Associate Director, Translational Applications, Mitra Biotech


  • Recreating the human TME by using fresh human tumour tissue, autologous serum and immune cells, and immune-targeted agents in a platform with 1:1 clinical outcome validated in over 2,000 patients
  • Interrogate the phenotypic changes in living tissue in response to standard-of-care agents, PD-1 and PD-L1 inhibitors to explore compound activity, mechanism of action and discover & validate biomarkers
  • Predict clinical efficacy and enrich clinical trials with responders

Afternoon Refreshment Break

Turning up the Heat on Cold Tumours

Generation of a Bispecific Immunomodulatory Antibody ATOR-1015 Targeting OX40 and CTLA-4


• Showcasing the in vitro evaluation of bispecific immunomodulatory antibodies targeting a checkpoint inhibitor and an agonist target
• Divulging the mode of action of these bispecific immunomodulatory antibodies using OX40 transgenic mice

Targeting CD39 and CD73 to Improve Anti-Tumour Immune Responses

  • Carine Paturel Director, Research and Drug Development , Innate Pharma


• Identifying humanised anti-CD39 and anti-CD73 antibodies that potently inhibit CD39 and CD73 enzyme activity
• Showcasing novel in vitro data from the targeting of CD39/CD73 on T cell responsiveness
• Documenting target expression in several tumour types

Panel Discussion: Determinants Of Sensitivity & Resistance To Immune Checkpoint Blockers In Solid Tumours


• Biological factors associated with response and resistance to PD-1 axis blockers in human solid tumours
• Current role and limitations of clinical biomarkers for prediction of response to immune checkpoint blockers
• Emerging signatures for prediction of response to immunostimulatory therapies using genomic and phenotypic analyses
• Exploring the role of beta-catenin signalling in non responsive tumours & TGF-beta activity in resistance to PD-1 pathway therapeutics

Close of Day One